Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.23 USD
-0.06 (-4.65%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.23 USD
-0.06 (-4.65%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
by Zacks Equity Research
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
New Strong Buy Stocks for November 3rd
by Zacks Equity Research
XRX, GVA, CUBI, LXU and ENLV have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2023.
New Strong Buy Stocks for October 27th
by Zacks Equity Research
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
New Strong Buy Stocks for October 19th
by Zacks Equity Research
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
by Zacks Equity Research
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.
Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.
Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
by Zacks Equity Research
Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.
Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
What's in the Cards for Enlivex (ENLV) This Earnings Season?
by Zacks Equity Research
Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.
Company News For Nov 5, 2019
by Zacks Equity Research
Companies In The News Are: WMGI, ENLV, CRNT, UAA